Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: Risks and perspective

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2648-2650

  Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EATING; EDITORIAL; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; JAW OSTEONECROSIS; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; ODYNOPHAGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOCIAL BEHAVIOR; SPEECH; SYSTEMIC THERAPY; TOOTH EXTRACTION;

DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; OSTEONECROSIS;

EID: 84890061777     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.6837     Document Type: Editorial

References (22)

1. Ruggiero SL, Dodson TB, Assael LA, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2-12, 2009
2. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Ossociation of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376, 2007
3. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
4. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117-120, 2009
5. Varun B, Sivakumar T, Nair BJ, et al: Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review. J Oral Maxillofac Pathol 16:210-214, 2012
6. Migliorati CA, Epstein JB, Abt E, et al: Osteonecrosis of the jaw and bisphosphonates in cancer: A narrative review. Nat Rev Endocrinol 7:34-42, 2011
7. Madrid C, Bouferrache K, Abarca M, et al: Bisphosphonate-related osteonecrosis of the jaws: How to manage cancer patients. Oral Oncol 46:468-470, 2010
8. Nicoletti P, Cartsos VM, Palaska PK, et al: Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: The role of RBMS3. Oncologist 17:279-287, 2012
9. Katz J, Gong Y, Salmasinia D, et al: Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 40:605-611, 2011
10. Migliorati CA, Mattos K, Palazzolo MJ: How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Assoc 141:562-566, 2010
11. Bauer JS, Beck N, Kiefer J, et al: Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg 40:277-282, 2012
12. Rathbone EJ, Brown JE, Marshall HC, et al: Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial subprotocol (BIG01/04). J Clin Oncol 31:2685-2691, 2013
13. Gnant M, Mlineritsch B, Stoeger H, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62- month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
14. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
15. Mauri D, Valachis A, Polyzos IP, et al: Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A meta-analysis. Breast Cancer Res Treat 116:433-439, 2009
16. Hoff AO, Toth B, Hu M, et al: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218:47-54, 2011
17. Slade GD: Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 25:284-290, 1997
18. Kyrgidis A, Triaridis S, Kontos K, et al: Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: A comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. Anticancer Res 32:3527-3534, 2012
19. Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
20. Coleman R, de Boer R, Eidtmann H, et al: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24:398-405, 2013
21. Paterson AH, Anderson SJ, Lembersky BC, et al: Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-742, 2012
22. Scott LJ, Muir VJ: Denosumab: In the prevention of skeletal-related events in patients with bone metastases from solid tumours. Drugs 71:1059-1069, 2011